Vanguard Portfolio Management (RARE) discloses 6.85M-share Ultragenyx stake on 13G/A
Rhea-AI Filing Summary
Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of 6,853,427 shares of Ultragenyx Pharmaceutical Inc. common stock on an amended Schedule 13G as of June 30, 2026. This represents 6.95% of the outstanding class.
Vanguard has sole voting power over 63,292 shares and sole dispositive power over all 6,853,427 shares, with no shared voting or dispositive power. The reported holdings include securities held by Vanguard funds and managed accounts over which the reporting business units exercise voting and/or dispositive authority, but exclude positions held by other Vanguard affiliates whose ownership is disaggregated. Vanguard notes that its investment companies and other managed accounts have the right to receive dividends and sale proceeds from these securities, and that no other single person’s interest in the reported securities exceeds 5% of the class.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficially owned financial
sole dispositive power financial
sole voting power financial
Investment Company Act of 1940 regulatory
percent of class financial
AI-generated analysis. How Rhea-AI works. Not financial advice.